Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P39 vs Xolair in Chronic Spontaneous Urticaria
NCT04426890Phase 3Completed
- Sponsor
- Celltrion
- Start
- Dec 2020
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of CT-P39 in chronic spontaneous urticaria (CSU) (6 arms), sponsored by Celltrion. Primary endpoints: Therapeutic Equivalence Based on Change From Baseline in Weekly Itch Severity Score (ISS7) at 12 weeks and Relative Potency of CT-P39 Compared With Xolair Based on Change From Baseline in ISS7 at 12 weeks. Started Dec 2020; status: completed.
02
Drugs
CT-P39
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT04426890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04426890.